GIMAP2 and metabolic dysfunction-associated steatohepatitis: Notably, apart from CXCL9, the other four SWDEGs (GIMAP2, ADAMTS5, GRAP, and PRF1) have not been extensively explored their roles in the pathogenesis of NASH and IBD in previous studies, which could be new potential biomarkers and targets for therapeutic interventions of the two diseases.